U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H20N2O3
Molecular Weight 264.3207
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VORINOSTAT

SMILES

C(CCCC(=NO)O)CCC(=Nc1ccccc1)O

InChI

InChIKey=WAEXFXRVDQXREF-UHFFFAOYSA-N
InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)

HIDE SMILES / InChI

Molecular Formula C14H20N2O3
Molecular Weight 264.3207
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021991s002lbl.pdf

Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL). Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). These enzymes catalyze the removal of acetyl groups from the lysine residues of histones proteins. In some cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic transcription factors causing hypoacetylation of core nucleosomal histones. By inhibiting histone deacetylase, vorinostat causes the accumulation of acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. The mechanism of the antineoplastic effect of vorinostat has not been fully characterized. Vorinostat is used for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. Vorinostat is marketed under the name Zolinza by Merck for the treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after two systemic therapies.

CNS Activity

Curator's Comment:: Vorinostat was shown to cross the blood-brain barrier in a mouse model of Huntington's disease. It inhibited the growth of GL26 GBM cells implanted into the brains of mice. Vorinostat treatment induced accumulation of acetylated histones H2B, H3, and H4 in patients with recurrent GBM.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.12 µM [IC50]
0.13 µM [IC50]
0.15 µM [IC50]
0.28 µM [IC50]
1.68 µM [IC50]
57.0 nM [IC50]
1.0 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Zolinza

Approved Use

Treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.

Launch Date

1.16000634E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.2 μM
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
0.83 uM
400 mg single, oral
dose: 400 mg
route of administration: oral
experiment type: single
co-administered:
VORINOSTAT plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
1.17 uM
400 mg 1 times / day steady, oral
dose: 400 mg
route of administration: oral
experiment type: steady
co-administered:
VORINOSTAT plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5.5 μM × h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
4.59 uM*h
400 mg single, oral
dose: 400 mg
route of administration: oral
experiment type: single
co-administered:
VORINOSTAT plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
5.59 uM*h
400 mg 1 times / day steady, oral
dose: 400 mg
route of administration: oral
experiment type: steady
co-administered:
VORINOSTAT plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
1.94 h
400 mg single, oral
dose: 400 mg
route of administration: oral
experiment type: single
co-administered:
VORINOSTAT plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
2.3 h
400 mg 1 times / day steady, oral
dose: 400 mg
route of administration: oral
experiment type: steady
co-administered:
VORINOSTAT plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
29%
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
Doses

Doses

DosePopulationAdverse events​
250 mg 2 times / day multiple, oral
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, 63 years (range: 38 - 74 years)
n = 5
Health Status: unhealthy
Condition: advanced multiple myeloma
Age Group: 63 years (range: 38 - 74 years)
Population Size: 5
Sources:
DLT: Fatigue...
Dose limiting toxicities:
Fatigue (grade 3, 1 patient)
Sources:
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Disc. AE: Thrombocytopenia, Anemia...
Other AEs: Hypotension, Sepsis...
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (grade 3-4, 8%)
Anemia (grade 3-4, 17%)
Deep vein thrombosis (grade 3-4, 25%)
Pyrexia (grade 3-4, 25%)
Pulmonary embolism (grade 3-4, 17%)
Other AEs:
Hypotension (grade 3-4, 17%)
Sepsis (grade 3-4, 8%)
Fatigue (all grades, 27%)
Diarrhea (11%)
Nausea (8%)
Dysgeusia (11%)
Weight loss (3%)
Vomiting (11%)
Anorexia (3%)
Blood creatinine increased (8%)
Dehydration (5%)
Anemia (5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Fatigue grade 3, 1 patient
DLT, Disc. AE
250 mg 2 times / day multiple, oral
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, 63 years (range: 38 - 74 years)
n = 5
Health Status: unhealthy
Condition: advanced multiple myeloma
Age Group: 63 years (range: 38 - 74 years)
Population Size: 5
Sources:
Diarrhea 11%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Dysgeusia 11%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Vomiting 11%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Anorexia 3%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Weight loss 3%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Anemia 5%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Dehydration 5%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Blood creatinine increased 8%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Nausea 8%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Fatigue all grades, 27%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Hypotension grade 3-4, 17%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Anemia grade 3-4, 17%
Disc. AE
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Pulmonary embolism grade 3-4, 17%
Disc. AE
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Deep vein thrombosis grade 3-4, 25%
Disc. AE
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Pyrexia grade 3-4, 25%
Disc. AE
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Sepsis grade 3-4, 8%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Thrombocytopenia grade 3-4, 8%
Disc. AE
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive
no (co-administration study)
Comment: vorinostat has no inhibitory effect on the tranport of vinblastine
Page: 4, 6, 27
no [IC50 79.8 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no
yes
yes
yes
yes
yes
yes
Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth.
2001
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
2001 Dec 1
Phosphorus-based SAHA analogues as histone deacetylase inhibitors.
2003 Aug 21
Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.
2003 Dec
Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin.
2003 Mar 1
Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
2003 May 1
Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors.
2003 May 1
Histone deacetylase inhibitors up-regulate the expression of tight junction proteins.
2004 Dec
QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids.
2004 Feb 9
Gateways to clinical trials.
2004 Jun
[Therapeutic targets in polyglutamine diseases].
2004 May
The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA).
2004 May
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
2004 May 15
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
2004 Nov
Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
2004 Oct
High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum.
2005
Histone deacetylase inhibitors in programmed cell death and cancer therapy.
2005 Apr
Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
2005 Aug
Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis.
2005 Aug
It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells.
2005 Aug 1
Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin.
2005 Dec
Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.
2005 Jan 17
Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.
2005 Jul
Effect of inhibitors of histone deacetylase on the induction of cell differentiation in murine and human erythroleukemia cell lines.
2005 Jul
Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
2005 Jul 1
A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells.
2005 Jul 28
The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells.
2005 Jun
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
2005 Jun 10
4-Hydroxybenzoyl derivative from the aqueous extract of the hydroid Campanularia sp.
2005 Mar
Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.
2005 Mar
[Histone deacetylase inhibitors as a new generation of anti-cancer agents].
2005 Mar 11
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
2005 Mar 15
Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo.
2005 May
Novel histone deacetylase inhibitors in the treatment of thyroid cancer.
2005 May 15
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
2005 Nov
Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus.
2005 Nov 1
Crystal structure of a bacterial class 2 histone deacetylase homologue.
2005 Nov 18
Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer.
2005 Sep
Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.
2005 Sep
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
2005 Sep 1
Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects.
2005 Sep 1
Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2.
2005 Sep 23
Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2.
2006 Apr 6
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
2006 Jan
SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.
2006 Jan
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
2006 Jan 1
SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis.
2006 Jul 1
Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
2006 Mar
Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation.
2006 Mar 3
Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases.
2006 May 15
Patents

Sample Use Guides

400 mg orally once daily with food. If patient is intolerant to therapy, the dose may be reduced to 300 mg orally once daily with food. If necessary, the dose may be further reduced to 300 mg once daily with food for 5 consecutive days each week.
Route of Administration: Oral
Concentrations of vorinostat higher than 0.5 uM significantly inhibited the upregulated gene expression of MMP-1 and MMP-13 induced by IL-1β, whereas 0.1 uM vorinostat showed no obvious effect. Conversely, 0.5 uM vorinostat or higher concentration increased the TIMP-1 expression.
Substance Class Chemical
Created
by admin
on Fri Jun 25 22:11:30 UTC 2021
Edited
by admin
on Fri Jun 25 22:11:30 UTC 2021
Record UNII
58IFB293JI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VORINOSTAT
INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
VORINOSTAT [MI]
Common Name English
NSC-759852
Code English
VORINOSTAT [ORANGE BOOK]
Common Name English
NSC-701852
Code English
N-HYDROXY-N'-PHENYLOCTANEDIAMIDE
Systematic Name English
NSC-748799
Code English
ZOLINZA
Brand Name English
VORINOSTAT [WHO-DD]
Common Name English
MK0683
Code English
VORINOSTAT [MART.]
Common Name English
MK-0683
Code English
VORINOSTAT [USAN]
Common Name English
OCTANEDIAMIDE, N-HYDROXY-N'-PHENYL-
Systematic Name English
VORINOSTAT [INN]
Common Name English
SUBEROYLANILIDE HYDROXAMIC ACID
Common Name English
VORINOSTAT [JAN]
Common Name English
VORINOSTAT [VANDF]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 177203
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
WHO-VATC QL01XX38
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
EU-Orphan Drug EU/3/11/854
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
LIVERTOX 1040
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
NCI_THESAURUS C1946
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
NDF-RT N0000175588
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
FDA ORPHAN DRUG 540116
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
WHO-ATC L01XX38
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
NDF-RT N0000175071
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
FDA ORPHAN DRUG 174203
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
FDA ORPHAN DRUG 169503
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL98
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
DRUG CENTRAL
4124
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
CAS
149647-78-9
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
MERCK INDEX
M11502
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY Merck Index
HSDB
7930
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
PUBCHEM
5311
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
RXCUI
194337
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY RxNorm
FDA UNII
58IFB293JI
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
MESH
C111237
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
INN
8661
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
NCI_THESAURUS
C1796
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
IUPHAR
6852
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
WIKIPEDIA
VORINOSTAT
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
EPA CompTox
149647-78-9
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
EVMPD
SUB23356
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
DRUG BANK
DB02546
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
BINDING
IC50
TARGET -> INHIBITOR
BINDING
IC50
METABOLIC ENZYME -> SUBSTRATE
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
TARGET -> INHIBITOR
BINDING
IC50
TARGET -> INHIBITOR
BINDING
IC50
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
BINDING
IC50
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
TARGET ORGANISM->INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
BINDING
IC50
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE INACTIVE -> PARENT
PLASMA
METABOLITE -> PARENT
METABOLITE INACTIVE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
METABOLITE INACTIVE -> PARENT
URINE
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
blood-to-plasma ratio PHARMACOKINETIC
Tmax PHARMACOKINETIC FED CONDITION

HIGH-FAT MEAL

Volume of Distribution PHARMACOKINETIC INTRAVENOUS ADMINISTRATION

DOSE

Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

FASTED CONDITION